Stryker has announced its preliminary financial results for the 2017 business year, during which it was able to generate strong year-on-year growth.
For the fourth quarter of the year, the company generated an estimated net sales total of $3.5 billion (GBP 2.56 billion), which represents a rise of ten percent compared to the corresponding quarter of 2016.
“Stryker has reported year-on-year growth of around ten percent for the fourth quarter and full-year periods of 2017.“
Meanwhile, for the full year, sales came to $12.4 billion, marking an increase of 9.9 percent on the previous year. Its orthopaedics, MedSurg and neurotechnology and spine businesses all contributed positively to this performance.
Key highlights of the quarter included strong sales of its Mako robots, with 35 sold globally and 65 percent of systems in the field upgraded to the Mako Total Knee application. This continued momentum contributed to US knee sales growth of 10.5 percent for Q4.
In 2018, the firm expects a modest headwind following the recent US tax reforms, which is expected to be manageable within Stryker's overall financial targets.
Kevin Lobo, chairman and chief executive officer of Stryker, said: "We continued our momentum with strong organic sales growth … I would like to thank our teams for delivering these results, which were well-balanced across businesses and geographies."
With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Medical Devices